Wave Life Sciences WVE Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Sarepta Therapeutics, Inc.SRPT

——

Beam TherapeuticsBEAM

——

Solid Biosciences Inc.SLDB

——

BiohavenBHVN

——

Other financials

Income statement

See full

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

See full

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

See full

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

See full

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Profitability

See full

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

See full

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Wave Life Sciences's accrued expenses and other liabilities?: Wave Life Sciences (WVE) reported accrued expenses and other liabilities of -$13.52M in Q1 2026.
How has Wave Life Sciences's accrued expenses and other liabilities changed year-over-year?: Wave Life Sciences's accrued expenses and other liabilities decreased by 1.9% year-over-year, from -$13.27M to -$13.52M.